Literature DB >> 22436237

Nitric oxide stress in sporadic inclusion body myositis muscle fibres: inhibition of inducible nitric oxide synthase prevents interleukin-1β-induced accumulation of β-amyloid and cell death.

Jens Schmidt1, Konstanze Barthel, Jana Zschüntzsch, Ingrid E Muth, Emily J Swindle, Anja Hombach, Stephan Sehmisch, Arne Wrede, Fred Lühder, Ralf Gold, Marinos C Dalakas.   

Abstract

Sporadic inclusion body myositis is a severely disabling myopathy. The design of effective treatment strategies is hampered by insufficient understanding of the complex disease pathology. Particularly, the nature of interrelationships between inflammatory and degenerative pathomechanisms in sporadic inclusion body myositis has remained elusive. In Alzheimer's dementia, accumulation of β-amyloid has been shown to be associated with upregulation of nitric oxide. Using quantitative polymerase chain reaction, an overexpression of inducible nitric oxide synthase was observed in five out of ten patients with sporadic inclusion body myositis, two of eleven with dermatomyositis, three of eight with polymyositis, two of nine with muscular dystrophy and two of ten non-myopathic controls. Immunohistochemistry confirmed protein expression of inducible nitric oxide synthase and demonstrated intracellular nitration of tyrosine, an indicator for intra-fibre production of nitric oxide, in sporadic inclusion body myositis muscle samples, but much less in dermatomyositis or polymyositis, hardly in dystrophic muscle and not in non-myopathic controls. Using fluorescent double-labelling immunohistochemistry, a significant co-localization was observed in sporadic inclusion body myositis muscle between β-amyloid, thioflavine-S and nitrotyrosine. In primary cultures of human myotubes and in myoblasts, exposure to interleukin-1β in combination with interferon-γ induced a robust upregulation of inducible nitric oxide synthase messenger RNA. Using fluorescent detectors of reactive oxygen species and nitric oxide, dichlorofluorescein and diaminofluorescein, respectively, flow cytometry revealed that interleukin-1β combined with interferon-γ induced intracellular production of nitric oxide, which was associated with necrotic cell death in muscle cells. Intracellular nitration of tyrosine was noted, which partly co-localized with amyloid precursor protein, but not with desmin. Pharmacological inhibition of inducible nitric oxide synthase by 1400W reduced intracellular production of nitric oxide and prevented accumulation of β-amyloid, nitration of tyrosine as well as cell death inflicted by interleukin-1β combined with interferon-γ. Collectively, these data suggest that, in skeletal muscle, inducible nitric oxide synthase is a central component of interactions between interleukin-1β and β-amyloid, two of the most relevant molecules in sporadic inclusion body myositis. The data further our understanding of the pathology of sporadic inclusion body myositis and may point to novel treatment strategies.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22436237     DOI: 10.1093/brain/aws046

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  22 in total

1.  Activation of osmolyte pathways in inflammatory myopathy and Duchenne muscular dystrophy points to osmoregulation as a contributing pathogenic mechanism.

Authors:  Boel De Paepe; Jean-Jacques Martin; Sandrine Herbelet; Cecilia Jimenez-Mallebrera; Estibaliz Iglesias; Cristina Jou; Joachim Weis; Jan L De Bleecker
Journal:  Lab Invest       Date:  2016-06-20       Impact factor: 5.662

2.  SHP-1-dependent macrophage differentiation exacerbates virus-induced myositis.

Authors:  Neva B Watson; Karin M Schneider; Paul T Massa
Journal:  J Immunol       Date:  2015-02-13       Impact factor: 5.422

Review 3.  Risk factors and disease mechanisms in myositis.

Authors:  Frederick W Miller; Janine A Lamb; Jens Schmidt; Kanneboyina Nagaraju
Journal:  Nat Rev Rheumatol       Date:  2018-04-20       Impact factor: 20.543

Review 4.  Mechanistic effects of IVIg in neuroinflammatory diseases: conclusions based on clinicopathologic correlations.

Authors:  Marinos C Dalakas
Journal:  J Clin Immunol       Date:  2014-04-11       Impact factor: 8.317

Review 5.  Diagnosis, pathogenesis and treatment of myositis: recent advances.

Authors:  P-O Carstens; J Schmidt
Journal:  Clin Exp Immunol       Date:  2014-03       Impact factor: 4.330

6.  Targeting protein homeostasis in sporadic inclusion body myositis.

Authors:  Mhoriam Ahmed; Pedro M Machado; Adrian Miller; Charlotte Spicer; Laura Herbelin; Jianghua He; Janelle Noel; Yunxia Wang; April L McVey; Mamatha Pasnoor; Philip Gallagher; Jeffrey Statland; Ching-Hua Lu; Bernadett Kalmar; Stefen Brady; Huma Sethi; George Samandouras; Matt Parton; Janice L Holton; Anne Weston; Lucy Collinson; J Paul Taylor; Giampietro Schiavo; Michael G Hanna; Richard J Barohn; Mazen M Dimachkie; Linda Greensmith
Journal:  Sci Transl Med       Date:  2016-03-23       Impact factor: 17.956

7.  Activation of the NLRP3 Inflammasome Is Associated with Valosin-Containing Protein Myopathy.

Authors:  Angèle Nalbandian; Arif A Khan; Ruchi Srivastava; Katrina J Llewellyn; Baichang Tan; Nora Shukr; Yasmin Fazli; Virginia E Kimonis; Lbachir BenMohamed
Journal:  Inflammation       Date:  2017-02       Impact factor: 4.092

Review 8.  Antibody Therapies in Autoimmune Inflammatory Myopathies: Promising Treatment Options.

Authors:  Rachel Zeng; Stefanie Glaubitz; Jens Schmidt
Journal:  Neurotherapeutics       Date:  2022-04-08       Impact factor: 6.088

Review 9.  Amyloid deposits and inflammatory infiltrates in sporadic inclusion body myositis: the inflammatory egg comes before the degenerative chicken.

Authors:  Olivier Benveniste; Werner Stenzel; David Hilton-Jones; Marco Sandri; Olivier Boyer; Baziel G M van Engelen
Journal:  Acta Neuropathol       Date:  2015-01-13       Impact factor: 17.088

10.  Cell stress molecules in the skeletal muscle of GNE myopathy.

Authors:  Charlotte Fischer; Konstanze Kleinschnitz; Arne Wrede; Ingrid Muth; Niels Kruse; Ichizo Nishino; Jens Schmidt
Journal:  BMC Neurol       Date:  2013-03-12       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.